Fig. 5.

The biodistribution and anti-tumor effect evaluation of MOFs. (A) In vivo fluorescence images of BALB/c mice bearing 4T1 tumor at 2 h, 6 h, 12 h, 24 h and 36 h post injection of BM and BMH and Ex-vivo fluorescence of major organs and tumors after treatment for 36 h. (B) The primary tumor growth curve during 14 d treatment (n = 5, *P < 0.05, **P < 0.01). (C) The H&E staining result of primary tumors after treatment with MOFs (scale bar=100 µm). (D) The Ki67 expression of primary tumors after treatment with MOFs (scale bar=50 µm). (E) The ROS generation in vivo after treatment with MOFs (scale bar=100 µm). (F) The GPX4 expression in vivo after treatment with MOFs (scale bar=100 µm).